Author of

• 28971

  +

  Lunch & Poster Display session (ID 58)

  • Event: ELCC 2019
  • Type: Poster Display session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1

  • 29049

    +

    96P - Impact of thrombocytosis and neutrophil-to-lymphocyte ratio before start of chemoradiotherapy on patient survival in inoperable stage III NSCLC (ID 587)

    12:30 - 13:00  |  Presenting Author(s): Michael Hoffmann
    • Abstract

    Background
    

    We aimed to evaluate an impact of thrombocytosis and neutrophil-to-lymphocyte ratio (NLR) before start of multimodal treatment on survival of patients with inoperable locally advanced non-small cell lung cancer (NSCLC).

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    Retrospective data of 99 patients (ECOG 0-1) with inoperable NSCLC stage III receiving definitive chemoradiotherapy (CRT) between 2010 and 2016 at our institute were analyzed. Complete blood count and neutrophil- to- lymphocyte ratio (NLR) before initiation of multimodal treatment were evaluated and correlated with EFS and OS.

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    The median age was 67 years and 63 % of patients were male. Median follow-up for the entire cohort was 17 months (range: 2 – 92). Patients with initial thrombocytosis (>401 x 109/L) demontrated a significantly shorter median EFS (7 vs. 14.5 months, p < 0.001, log-rank test) and OS (11 vs. 23 months, p = 0.002, log-rank test) vs. patients with normal platelet count. Patients with NLR >3.5 before start of multimodal treatment had a significantly worse prognosis than patients with lower initial NLR (0.78 – 3.5), (17.2 vs 29.3 months, p = 0.041, log-rank test).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    Initial thrombocytosis and NLR > 3.5 were associated with shorter survival in patients with inoperable stage III NSCLC treated with definitive CRT.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    The authors.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25